Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.addr.2020.12.011 http://scihub22266oqcxt.onion/10.1016/j.addr.2020.12.011 33359141!7759095!33359141     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Adv+Drug+Deliv+Rev 2021 ; 170 (ä): 1-25 Nephropedia Template TP {{tp|p=33359141|t=2021. COVID-19 vaccines: The status and perspectives in delivery points of view |pdf=|usr=}}{{33359141}} gab.com Text COVID-19 vaccines: The status and perspectives in delivery points of view JO: Adv Drug Deliv Rev http://www.kidney.de/pget.php?&tw=1&pmid=33359141 #FOAvip Due to the high prevalence and long incubation periods often without symptoms, the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected millions of individuals globally, causing the coronavirus disease 2019 (COVID-19) pandemic. Even with the recent approval of the anti-viral drug, remdesivir, and Emergency Use Authorization of monoclonal antibodies against S protein, bamlanivimab and casirimab/imdevimab, efficient and safe COVID-19 vaccines are still desperately demanded not only to prevent its spread but also to restore social and economic activities via generating mass immunization. Recent Emergency Use Authorization of Pfizer and BioNTech's mRNA vaccine may provide a pathway forward, but monitoring of long-term immunity is still required, and diverse candidates are still under development. As the knowledge of SARS-CoV-2 pathogenesis and interactions with the immune system continues to evolve, a variety of drug candidates are under investigation and in clinical trials. Potential vaccines and therapeutics against COVID-19 include repurposed drugs, monoclonal antibodies, antiviral and antigenic proteins, peptides, and genetically engineered viruses. This paper reviews the virology and immunology of SARS-CoV-2, alternative therapies for COVID-19 to vaccination, principles and design considerations in COVID-19 vaccine development, and the promises and roles of vaccine carriers in addressing the unique immunopathological challenges presented by the disease. Twit Text FOAVip COVID-19 vaccines: The status and perspectives in delivery points of view ????Adv Drug Deliv Rev http://www.kidney.de/pget.php?&tw=1&pmid=33359141 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33359141 #FOAvip English Wikipedia <ref>{{Cite pmid|33359141}}</ref> COVID-19 vaccines: The status and perspectives in delivery points of view #MMPMID33359141 Chung JY; Thone MN; Kwon YJ Adv Drug Deliv Rev 2021[Mar]; 170 (ä): 1-25 PMID33359141show ga Due to the high prevalence and long incubation periods often without symptoms, the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected millions of individuals globally, causing the coronavirus disease 2019 (COVID-19) pandemic. Even with the recent approval of the anti-viral drug, remdesivir, and Emergency Use Authorization of monoclonal antibodies against S protein, bamlanivimab and casirimab/imdevimab, efficient and safe COVID-19 vaccines are still desperately demanded not only to prevent its spread but also to restore social and economic activities via generating mass immunization. Recent Emergency Use Authorization of Pfizer and BioNTech's mRNA vaccine may provide a pathway forward, but monitoring of long-term immunity is still required, and diverse candidates are still under development. As the knowledge of SARS-CoV-2 pathogenesis and interactions with the immune system continues to evolve, a variety of drug candidates are under investigation and in clinical trials. Potential vaccines and therapeutics against COVID-19 include repurposed drugs, monoclonal antibodies, antiviral and antigenic proteins, peptides, and genetically engineered viruses. This paper reviews the virology and immunology of SARS-CoV-2, alternative therapies for COVID-19 to vaccination, principles and design considerations in COVID-19 vaccine development, and the promises and roles of vaccine carriers in addressing the unique immunopathological challenges presented by the disease. |Animals[MESH] |Antiviral Agents/*administration & dosage/immunology[MESH] |COVID-19 Vaccines/*administration & dosage/chemical synthesis/immunology[MESH] |COVID-19/*epidemiology/immunology/*prevention & control[MESH] |Drug Development/*methods/trends[MESH] |Humans[MESH] |Immunization Programs/methods/trends[MESH]COVID-19 vaccines: The status and perspectives in delivery points of v(epmc).pdf DeepDyve Pubget Overpricing